News

Articles

With funding from the federal government, Merck will expand capacity to produce J&J’s COVID-19 vaccine.

Merck to Manufacture J&J Vaccine

The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.

Roche and Cambridge Quantum Computing Use Algorithms for Early Alzheimer's Drug Research

The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.

SPT Labtech Strengthens Automation Services with BioMicroLab Acquisition

The new ultra-sensitive second-generation micro-chip technology is a key enabler in advanced single-cell proteomics workflow.

PharmaFluidics Offers Second-Gen µPAC Technology for Single Cell Proteomics

Through the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities.

Seven Bridges to Support Pfizer’s Data Management Solution for Single-Cell RNA Sequencing

The companies will integrate Welldoc’s digital insulin management solution, BlueStar, into Eli Lilly’s connected insulin solutions.

Eli Lilly and Welldoc to Collaborate on New Digital Insulin Management Solution

The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.

Novavax Expands COVID-19 Collaboration and License Agreement with SK Bioscience 

The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.

Novartis and the Bill & Melinda Gates Foundation Team Up to Develop Gene Therapy for Sickle Cell Disease

4D pharma has signed a clinical trial collaboration and supply agreement with Merck and Pfizer for Bavencio (avelumab).

4D pharma Signs Clinical Trial Collaboration and Supply Agreement with Merck and Pfizer

Exscientia has formed a partnership with the ARUK-ODDI for the development of medicines targeting neuroinflammation to treat Alzheimer’s disease.

Exscientia Partners with University of Oxford on Alzheimer’s Treatments

The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.

AstraZeneca and IDT Biologika Plan Vaccine Capacity Expansion

The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers. 

FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Lymphoma Treatment

Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.

AbbVie to Collaborate with Caribou Biosciences on CAR-T Cell Therapeutics

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.

Big Pharma Takes on Vaccine Production

The vaccine met the primary endpoint with a vaccine efficacy of 89.3% in its Phase III trial in the United Kingdom and a vaccine efficacy of 49% in HIV-positive participants and 60% in HIV-negative participants in a South African Phase IIb trial. 

Novavax Shares Data from UK and South Africa COVID-19 Vaccine Candidate Trials 

The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.

J&J’s COVID-19 Vaccine Candidate Effective in Preventing Moderate to Severe COVID-19

Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.

Takeda and Evozyne Enter into Gene Therapy Collaboration 

The company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, to focus on advancing its two SARS-CoV-2/COVID-19 therapeutic candidates, MK-4482 and MK-7110. 

Merck Halts Development of its COVID-19 Vaccine Candidates

The drug offers immediate post-exposure protection against the virus and will serve as a counterpart to the vaccine during its early phases.

Biopharma News